S1.

Baseline and post-progression characteristics of patients who continued CBPD and those who did not (N=261)

Characteristics	Total	Continued CBPD		χ2	P
		No	Yes
CBPD, crizotinib beyond progressive disease; ECOG PS, Eastern Cooperative Oncology Group performance status; NA, missing data; PFS, progression-free survival; ALK, anaplastic lymphoma kinase.
Age (year)				1.018	0.313
<65	228	103	125
≥65	33	18	15
Sex				0.601	0.438
Male	127	62	65
Female	134	59	75
Smoking status				3.933	0.047
Former-smoker	75	42	33
Never-smoker	186	79	107
Histology				0.067	0.796
Adenocarcinoma	249	115	134
Non-adenocarcinoma	12	6	6
ECOG PS score				10.322	0.001
0−1	238	103	135
2−3	23	18	5
Stage				0.343	0.558
IIIA−IIIB	13	5	8
IV	248	116	132
Brain metastasis				1.668	0.196
Yes	59	23	36
No	202	98	104
Line of therapy before crizotinib				0.010	0.921
0	154	71	83
≥1	107	50	57
Progression pattern				67.695	<0.001
Intracranial progress	94	15	79
Extracranial progress	113	61	52
Comprehensive progress	42	36	6
NA	12	9	3
Initial PFS with crizotinib				9.959	0.002
≥median	100	34	66
<median	161	87	74
Next-generation ALK inhibitors after progression on crizotinib				9.430	0.002
Yes	83	50	33
No	178	71	107